Tokenize physical hardware and manufactured goods into milestone-gated claims. Founders fund production without equity dilution; backers get verifiable factory milestone escrow and secondary liquidity. Capital releases only against evidence approved by claim holders.
Off-Grid Solar Vaccine Cold-Chain Unit
Hardware innovation is trapped between dilutive venture rounds and crowdfunding platforms that hold backers accountable to nothing.
Founders surrender 20-35% equity per funding round simply to purchase tooling dies and raw inventory.
Backers hand over full payment upfront with no escrow, no tranche control, and no recourse if the build stalls.
Capital is escrowed on-chain and released tranche by tranche, only after claim holders approve production evidence.
Four stages from a hardware concept to released capital, each one enforced by the contracts rather than by trust.
A founder publishes the product, bill of materials, target raise and manufacturing plan, then defines the escrow milestone schedule.
Capital is committed and custodied in MilestoneEscrow. Tranche amounts are set by the founder up front and must sum exactly to the funding target, so every unit of capital has an assigned release condition.
At each milestone the founder submits production evidence to IPFS. Vote weight is snapshotted at submission, and claim holders approve or reject within the review window. A protocol oracle can escalate a disputed milestone.
An approved milestone releases its tranche to the founder. Claims remain tradeable throughout on the secondary market, so holders are not locked in until delivery.
Hardware builds currently accepting capital commitments.
Off-grid solar vaccine cold-chain refrigeration for rural clinics.
Modular multi-spectral LiDAR payload for infrastructure inspection.
Force-controlled end effector for light assembly cobots.
Any build with a bill of materials, a production schedule and a verifiable output can be underwritten.
Register a hardware build, define your milestone schedule, and raise against production output, not equity. Capital releases only when claim holders approve the evidence.